An expanded label on Medivation Inc.’s signature prostate cancer drug will net the San Francisco company an additional $90 million from partner Astellas Pharma Inc.
The Food and Drug Administration said Xtandi, which the agency approved in August 2012 to treat men with metastatic castration-resistant prostate cancer who previously received the chemotherapy drug docetaxel, now can be used before chemotherapy, the companies said Wednesday.
The new indication means more than the addition of a few more words on the label of oral Xtandi capsules, which cost about $7,500 a month.
Hey, check out all the engineering jobs. Post your resume today!
